1187450-65-2

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 203321-86-2 6-tert-butoxycarbonylamino-pyridine-2-carboxylic acid ethyl ester 
• 1187450-49-2 tert-butyl (tert-butoxycarbonyl(6-(hydroxymethyl)pyridin-2-yl)amino)acetate 
• 1187450-77-6 tert-butyl (tert-butoxycarbonyl{6-[(pyridin-3-ylsulfonyl)aminomethyl]pyridin-2-yl}amino)acetate 
• 143426-49-7 1-(4-hydroxymethylphenyl)-1H-pyrazole 
• 1187451-29-1 tert-butyl [tert-butoxycarbonyl(6-formylpyridin-2-yl)amino]acetate 
• 1187451-32-6 tert-butyl [(6-aminomethylpyridin-2-yl)tert-butoxycarbonylamino]acetate 
• 1187451-30-4 tert-butyl [tert-butoxycarbonyl(6-hydroxyiminomethylpyridin-2-yl)amino]acetate 
• 1187451-25-7 tert-butyl [tert-butoxycarbonyl(6-ethoxycarbonylpyridine-2-yl)amino]acetate 

Downstream Products

• 1187451-41-7 (6-((4-(pyrazol-1-yl)benzyl)(pyridin-3-ylsulfonyl)aminomethyl)pyridin-2-ylamino)acetic acid 
• 1273387-12-4 (2,2,2-trifluoroethyl) (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate 
• 1187451-19-9 isopropyl 2-{[6-({N-[4-(1H-pyrazol-1-yl)benzyl]pyridine-3-sulfonamido}methyl)pyridin-2-yl]amino}acetate 

Relevant academic research and scientific papers

Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl

EP2 receptor agonists are expected to be effective ocular hypotensive agents; however, it has been suggested that agonism to other EP receptor subtypes may lead to undesirable effects. Through medicinal chemistry efforts, we identified a scaffold bearing a (pyridin-2-ylamino)acetic acid moiety as a promising EP2-selective receptor agonist. (6-((4-(Pyrazol-1-yl)benzyl)(pyridin-3-ylsulfonyl)aminomethyl)pyridin-2-ylamino)acetic acid 13ax (omidenepag, OMD) exerted potent and selective activity toward the human EP2 receptor (h-EP2). Low doses of omidenepag isopropyl (OMDI), a prodrug of 13ax, lowered intraocular pressure (IOP) in ocular normotensive monkeys. OMDI was selected as a clinical candidate for the treatment of glaucoma.

PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA

The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1): wherein R1, R2 and R3 each independe

SUBSTITUTED CARBONYL COMPOUNDS

This is to provide a novel substituted carbonyl compound represented by the following formula (I) having an excellent bronchodilatory action based on potent EP2 agonistic action and useful for treatment of respiratory diseases. A compound represented by t

PYRIDYLAMINOACETIC ACID COMPOUND

The present invention provides a novel pyridylaminoacetic acid compound represented by the following formula (1): (wherein R1, R2, R3, Y and Z are as defined in the description and claims), or a pharmacologically acceptabl